Results 1 to 10 of about 85,599,608 (253)

Pleiotropic Benefits of DPP-4 Inhibitors Beyond Glycemic Control

Clinical Medicine Insights: Endocrinology and Diabetes, 2021
Jeong Hyun Park, Seon Mee Kang
exaly  

People also looked at

Frontiers in Endocrinology, 2019
Baptist Gallwitz
exaly  

Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4)

Best Practice & Research Clinical Endocrinology & Metabolism, 2009
Baptist Gallwitz
exaly  

Worsening Heart Failure During the Use of DPP-4 Inhibitors: Pathophysiological Mechanisms, Clinical Risks, and Potential Influence of Concomitant Antidiabetic Medications.

JACC: Heart Failure, 2018
Milton Packer
exaly  

HLA-DQB1*03:01 as a Biomarker for Genetic Susceptibility to Bullous Pemphigoid Induced by DPP-4 Inhibitors

Journal of Investigative Dermatology, 2018
Ken Muramatsu, Kyu Yong Cho, Hideyuki Ujiie   +2 more
exaly  

The Unique Properties of Dipeptidyl-peptidase IV (DPP IV I CD26) and the Therapeutic Potential of DPP IV Inhibitors

Current Medicinal Chemistry, 1999
Koen Augustyns, Christine Durinx, F Goossens   +2 more
exaly  

Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review

Clinical Therapeutics, 2012
Byron J. Hoogwerf, Robert R Henry, Tamara Darsow   +2 more
exaly  

Dipeptidyl peptidase-4(DPP-4) inhibitors: promising new agents for autoimmune diabetes

Clinical and Experimental Medicine, 2018
Chunlan Zhang, Zhiguang Zhou, Peilin Zheng   +2 more
exaly  

Discovery and pharmacological characterization of -[2-({2-[(2)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor

Bioorganic and Medicinal Chemistry, 2011
Motohiro Takeda, Satoko Yamashita, Yoshika Yasuda   +2 more
exaly  

The New insights from DPP-4 inhibitors: their potential immune modulatory function in autoimmune diabetes

Diabetes/Metabolism Research and Reviews, 2014
Chunlan Zhang
exaly